Drug and Device Combination (2009 - 2014)

Table of Contents

1. Introduction

• 1.1. Key Take Aways
• 1.2. Report Description
• 1.3. Markets Covered
• 1.4. Stakeholders

2. Summary

3. Market Overview

• 3.1. Evolution Of Drug-Device Combination
• 3.2. Driving Factors Analysis For Drug-Device Combination Market
• 3.3. Drivers
  • 3.3.1. Increased Efficiency
  • 3.3.2. Exploiting Existing Technologies
  • 3.3.3. Accelerated Approval Process
  • 3.3.4. Medical Insurance Coverage
  • 3.3.5. Rising Awareness
• 3.4. Restraints
  • 3.4.1. Issues Involved In Cross Industry Partnerships
  • 3.4.2. Drug-Device Combination Products Are Expensive
  • 3.4.3. Jurisdiction Issues
  • 3.4.4. Fear Of Possible Side-Effects
• 3.5. Opportunities
  • 3.5.1. Reduction In Investment Costs
  • 3.5.2. Streamlining Issues In Partnerships
  • 3.5.3. Reduction In The Overall Cost Of Treatment
  • 3.5.4. Market Participation By Smaller Companies

4. Drug-Device Combination Products

• 4.1. Antimicrobial Catheter
  • 4.1.1. Drivers
    • 4.1.1.1. Reduced Incidences Of Infection In Intensive Care Units
    • 4.1.1.2. Over All Cost Reduction
    • 4.1.1.3. Certain Catheters Are Prone To Infections
    • 4.1.1.4. Reimbursement Issues
    • 4.1.1.5. Presence Of Big Players In The Antimicrobial Catheters Market
    • 4.1.1.6. Awareness Of Antimicrobial Agents Used For Coating On The Catheters
    • 4.1.1.7. Demand Unaffected By The Economic Downturn
  • 4.1.2. Restraints
    • 4.1.2.1. Price Constraints
    • 4.1.2.2. Lack Of Awareness In Developing Countries
  • 4.1.3. Key Players & Their Recent Developments
  • 4.1.4. Urological Catheters
    • 4.1.4.1. Drivers
      • 4.1.4.1.1. Prevention Of Several Nosocomial Infections
      • 4.1.4.1.2. Beneficial For Women And Baby Boomers
      • 4.1.4.1.3. Reduced Health Care Costs
      • 4.1.4.1.4. Increased Applications
    • 4.1.4.2. Restraints
      • 4.1.4.2.1. Alternatives To Prolonged Catherization
      • 4.1.4.2.2. Reimbursement Issues
      • 4.1.4.2.3. Key P Layers And Their Recent Developments
    • 4.1.4.3. Dialysis Catheter
      • 4.1.4.3.1. Key Players And Their Recent Developments:
      • 4.1.4.3.2. Hemodialysis Catheters
      • 4.1.4.3.3. Peritoneal Catheters
        • 4.1.4.3.3.1. Drivers
      • 4.1.4.4. Urinary Catheters
        • 4.1.4.4.1. Drivers
        • 4.1.4.4.2. Key Players And Their Recent Developments
        • 4.1.4.4.3. Indwelling Catheters
          • 4.1.4.4.3.1. Drivers
          • 4.1.4.4.3.2. Restraints
          • 4.1.4.4.3.3. Key Players And Their Recent Developments
        • 4.1.4.4.4. External Catheter
  • 4.1.5. Cardiovascular Catheters
    • 4.1.5.1. Drivers
      • 4.1.5.1.1. Indispensability Associated With These Catheters
      • 4.1.5.1.2. Suitable In Emergency Operations
      • 4.1.5.1.3. Rising Number Of Obesity Aiding The Growth Of The Procedures That Use These Products
      • 4.1.5.1.4. Interventional Procedures Have Better Success Ratio
    • 4.1.5.2. Restraints
      • 4.1.5.2.1. Usage Avoided Due To High Cost And Subsequent Reimbursement Issue
      • 4.1.5.2.2. Incidence Of Infections Due To The Use Of Non Antimicrobial Coated Catheter Not Known
      • 4.1.5.2.3. Competition From New Technologies And Devices
    • 4.1.5.3. Opportunities
      • 4.1.5.3.1. Awareness Of Surgeons
      • 4.1.5.3.2. Resolving Reimbursement Structure
      • 4.1.5.3.3. Decreasing Prices
  • 4.1.6. Oximetry Catheters
    • 4.1.6.1. Drivers
      • 4.1.6.1.1. Reduction In Catheter Related Blood Stream Infections
      • 4.1.6.1.2. Prolonged Fight Against Micro Organisms
      • 4.1.6.1.3. Overall Cost Of Hospitalization Will Go Down
      • 4.1.6.1.4. Popularity Of Uncoated Variant
    • 4.1.6.2. Key Players And Their Recent Developments
  • 4.1.7. Thermodilution Catheters
    • 4.1.7.1. Drivers
      • 4.1.7.1.1. Fatal Infections Are Avoided
      • 4.1.7.1.2. Increased Usage Likely In Near Future
      • 4.1.7.1.3. Increasing Complications Of The Heart
    • 4.1.7.2. Restraints
      • 4.1.7.2.1. Uncoated Thermodilution Catheters Are Cheaper
      • 4.1.7.2.2. Fear Of Resistance From Microorganism Strains
      • 4.1.7.2.3. Innovations In Pharmaceutical Therapies
  • 4.1.8. Wound Drainage Catheters
    • 4.1.8.1. Drivers
      • 4.1.8.1.1. Useful In Several Surgeries
      • 4.1.8.1.2. Protection From Wide Variety Of Micro Organisms
      • 4.1.8.1.3. Elimination Of The Risk Of Nosocomial Infections On The Wound Sites
    • 4.1.8.2. Restraints
      • 4.1.8.2.1. Proper Handling Required
• 4.2. Advanced Wound Care Products
  • 4.2.1. Drivers
    • 4.2.1.1. Multiple Advantages Over Conventional Wound Care Products
    • 4.2.1.2. Supports Healing Process Of The Skin
    • 4.2.1.3. Advanced Gel Based Products Accelerate Healing Process
    • 4.2.1.4. Prevention Of Bacterial Colonization On Sutures
    • 4.2.1.5. Reduction In The Cost Of Hospitalization
    • 4.2.1.6. Less Frequent Change Of Dressings Required
  • 4.2.2. Restraints
    • 4.2.2.1. Lack Of Product Differentiation Leading To Price Wars
    • 4.2.2.2. Minimally Invasive Surgeries Are Stunting The Demand Of Wound Care Products
  • 4.2.3. Opportunities
    • 4.2.3.1. Focus On Research
    • 4.2.3.2. Raise Awareness Of The Care Providers
    • 4.2.3.3. Specially Developed Wound Dressing Products
  • 4.2.4. Key Players And Their Recent Developments
  • 4.2.5. Antibiotic Wound Care
    • 4.2.5.1. Drivers
      • 4.2.5.1.1. Treatment Is Conducive For Wide Range Of Patients
      • 4.2.5.1.2. Low Risk Of Infections As Silver Is An Ingredient In The Product
      • 4.2.5.1.3. Nanotechnology Paves The Way For Improved Formulations
      • 4.2.5.1.4. Target Patients
    • 4.2.5.2. Restraints
      • 4.2.5.2.1. Cost Constraint
      • 4.2.5.2.2. Reimbursement Issues
    • 4.2.5.3. Opportunities
      • 4.2.5.3.1. Rising Awareness About The Risk Of Infections
      • 4.2.5.3.2. Edification Of Medical Practitioners
      • 4.2.5.3.3. Ageing Baby Boomers
    • 4.2.5.4. Key Players And Their Recent Developments
• 4.3. Bone Graft Substitutes
  • 4.3.1. Drivers
    • 4.3.1.1. Shortage Of Donors
    • 4.3.1.2. Substitutes Satisfying Ideal Properties Of Bone
    • 4.3.1.3. Virtual Elimination Of The Risk Of Infection
    • 4.3.1.4. Improved Life Expectancy
    • 4.3.1.5. Increasing Need For Orthopedic Procedures
  • 4.3.2. Restraints
    • 4.3.2.1. ' One Size Fits All' Approach Not Possible
    • 4.3.2.2. Procedure Not Affordable For All
  • 4.3.3. Key Players And Their Recent Developments
  • 4.3.4. Ceramic Based Bone Graft Substitute
    • 4.3.4.1. Drivers
      • 4.3.4.1.1. Most Popular Bone Graft Substitutes
      • 4.3.4.1.2. Compatibility With New Technology
      • 4.3.4.1.3. Risk Of Transference Of Fatal Diseases Eliminated
      • 4.3.4.1.4. Availability In Various Forms Gives Wider Choice For Applications
      • 4.3.4.1.5. Close Proximity Of Composition To Natural Bone
    • 4.3.4.2. Restraints
      • 4.3.4.2.1. Stand Alone Ceramic Products Are Brittle
      • 4.3.4.2.2. Application Limited To Non Load Bearing Sites
      • 4.3.4.2.3. Newer Technology Stunting The Stand Alone Ceramics Market
    • 4.3.4.3. Ceramic Based Bone Graft Substitutes Mixed With Calcium Phosphate
      • 4.3.4.3.1. Drivers
      • 4.3.4.3.2. Restraints
      • 4.3.4.3.3. Opportunities
      • 4.3.4.3.4. Key Players And Their Recent Developments
  • 4.3.5. Allograft Based Bone Graft Substitutes
    • 4.3.5.1. Drivers
      • 4.3.5.1.1. Totally Natural Enables Faster Healing
      • 4.3.5.1.2. Wide Array Of Choice For Various Applications
      • 4.3.5.1.3. Extraction Of Dbm Helps In Spine Fusion
      • 4.3.5.1.4. Localized Application Of Dbm Enables Faster Healing
    • 4.3.5.2. Restraints
      • 4.3.5.2.1. Risk Of Disease Diffusion Not Entirely Eliminated
      • 4.3.5.2.2. Success Depends On The Site Of Application
    • 4.3.5.3. Opportunities
      • 4.3.5.3.1. Wider Adoption Of New Technology
    • 4.3.5.4. Key Players And Their Recent Developments
  • 4.3.6. Factor Based Bone Graft Substitute
    • 4.3.6.1. Drivers
      • 4.3.6.1.1. Cellular Activity Made Possible In The Bone
      • 4.3.6.1.2. Removal Of Risks Of Toxicity
      • 4.3.6.1.3. Availability Of Supporting Technology
    • 4.3.6.2. Restraints
      • 4.3.6.2.1. Several Products Yet To Receive Marketing Approval
      • 4.3.6.2.2. No Guaranteed Results
      • 4.3.6.2.3. Production Process Incurs High Cost
    • 4.3.6.3. Opportunities
      • 4.3.6.3.1. Effectiveness In Treating Spinal Fusion
      • 4.3.6.3.2. More ' Factors' To Boost The Market
    • 4.3.6.4. Key Players And Their Recent Developments
  • 4.3.7. Cell Based Bone Graft Substitutes
    • 4.3.7.1. Drivers
      • 4.3.7.1.1. Most Adaptive To Human Body Among All Bone Graft Substitute Variants
      • 4.3.7.1.3. Faster Healing
      • 4.3.7.1.4. Simple Process Of Extraction
    • 4.3.7.2. Restraints
      • 4.3.7.2.1. Limited Results In Practice
      • 4.3.7.2.2. Supporting Technologies Not Available
      • 4.3.7.2.3. Several Regulatory Issues Yet To Be Resolved
    • 4.3.7.3. Opportunities
      • 4.3.7.3.1. Successful Results
      • 4.3.7.3.2. Advancement In Supporting Technologies
    • 4.3.7.4. Key Players And Their Recent Developments
• 4.4. Antibiotic Bone Cements
  • 4.4.1. Drivers
    • 4.4.1.1. Faster Healing Because Of Localized Treatment
    • 4.4.1.2. Prevention Of Infections
  • 4.4.2. Restraints
    • 4.4.2.1. Low Bacterial Resistance
    • 4.4.2.2. Prone To Allergic Reactions
    • 4.4.2.3. Expensive
  • 4.4.3. Key Players And Their Recent Developments
• 4.5. Drug Eluting Stents
  • 4.5.1. Drivers
    • 4.5.1.1. Increased Life Expectancy
    • 4.5.1.2. Interventional Procedures Have Higher Effectiveness
    • 4.5.1.3. Global Acceptance Of Drug Eluting Stent Technologies
    • 4.5.1.4. Reduces The Need For Repeat Procedures
  • 4.5.2. Restraints
    • 4.5.2.1. Risk Of Clots For Some Patients
    • 4.5.2.2. Adoption Of Better Cholesterol Fighting Drugs
    • 4.5.2.3. Bare Metal Stents Cheaper Than Drug Eluting Stents
  • 4.5.3. Opportunities
    • 4.5.3.1. Fda' s Support For Drug Eluting Stents
    • 4.5.3.2. New Generation Drug Eluting Stent
  • 4.5.4. Key Players And Their Recent Developments
  • 4.5.5. Coronary Stents
    • 4.5.5.1. Drivers
      • 4.5.5.1.1. Growing Popularity Of Minimally Invasive Surgery
      • 4.5.5.1.2. Prevention Of Reblockage
      • 4.5.5.1.3. Reduced Instances Of Deaths By Heart Attacks
      • 4.5.5.1.4. Diminished Need For Repeated Procedures
      • 4.5.5.1.5. Obesity And Other Factors Driving Cardiac Related Issues
    • 4.5.5.2. Restraints
      • 4.5.5.2.1. Limited Applications
      • 4.5.5.2.2. ' Off-Label' Applications
      • 4.5.5.2.3. Increased Restrictions Following Controversy
      • 4.5.5.2.4. Possibility Of Side Effects Due To Drug Therapy Following Surgery
    • 4.5.5.3. Opportunities
      • 4.5.5.3.1. Possibility Of Increased Applications
      • 4.5.5.3.2. Supporting Technology Reduces The Risk Of In-Stent Late Thrombosis
    • 4.5.5.4. Key Players And Their Recent Developments
  • 4.5.6. Peripheral Vascular Stent
    • 4.5.6.1. Drivers
      • 4.5.6.1.1. Alleviation Of Pain In The Aged Population
      • 4.5.6.1.2. Severe Results Are Eliminated
      • 4.5.6.1.3. Prevalence Of Cigarette Smoking Acts As A Driver
    • 4.5.6.2. Restraints
      • 4.5.6.2.1. Limited Data Available Due To Ignorance Of The Disease
      • 4.5.6.2.2. Lack Of Awareness Of Physicians
    • 4.5.6.3. Key Players And Their Recent Developments
• 4.6. Photodynamic Therapy
  • 4.6.1. Drivers
    • 4.6.1.1. Localized Treatment Increases The Effect Of The Therapy
    • 4.6.1.2. Less Time Gap Between Consumption Of Drug And Light Treatment
    • 4.6.1.3. Advantages Over Antibiotics
    • 4.6.1.4. Treatment Is Inexpensive
  • 4.6.2. Restraints
    • 4.6.2.1. Competition From Traditional Treatments
    • 4.6.2.2. Side Effects
  • 4.6.3. Opportunities
    • 4.6.3.1. Advanced Research Will Help To Treat Larger Solid Tumors
    • 4.6.3.2. Promising Field Of Non Invasive Anti Tumor Therapy
  • 4.6.4. Key Players And Their Recent Developments
  • 4.6.5. Aminolevulinic Acid
    • 4.6.5.1. Drivers
      • 4.6.5.1.1. Accuracy In Treatment
      • 4.6.5.1.2. Increase In Potential Size
      • 4.6.5.1.3. Increased Potential In Selected Markets
      • 4.6.5.1.4. Minimally Invasive Nature Is Attractive
      • 4.6.5.1.5. New Avenues Of Treatment
      • 4.6.5.1.6. Cheaper Than Other Alternatives
    • 4.6.5.2. Restraints
      • 4.6.5.2.1. Application Limited To Selected Areas Of The Body
      • 4.6.5.2.2. Prone To Photosensitivity
      • 4.6.5.2.3. Other More Efficient Treatments Are Available
    • 4.6.5.3. Opportunities
      • 4.6.5.3.1. Application Limited To Certain Geographical Areas
      • 4.6.5.3.2. Innovation Will Lead To Better Results
  • 4.6.6. Porfimer Sodium
    • 4.6.6.1. Drivers
      • 4.6.6.1.1. A Popular Form Of Treatment
      • 4.6.6.1.2. No Long Term Side Effects
      • 4.6.6.1.3. Number Of Applications
      • 4.6.6.1.4. Treatment Suitable For Patients Who Do Not Qualify For Other Treatments
    • 4.6.6.2. Restraints
      • 4.6.6.2.1. Treatment Is Not Independent
      • 4.6.6.2.2. Success Depends Upon The Stage Of The Disease
      • 4.6.6.2.3. Treatment Eliminates Extensive Forms Of Cancer
      • 4.6.6.2.4. Presence Of Side Effects
    • 4.6.6.3. Key Players And Their Recent Developments
  • 4.6.7. Verteporfin
    • 4.6.7.1. Drivers
      • 4.6.7.1.1. Treats Macular Degeneration Of The Wet Type
      • 4.6.7.1.2. Targeted Treatment Is Effective On Diseased Area
    • 4.6.7.2. Restraints
      • 4.6.7.2.1. Repeated Procedures Required
      • 4.6.7.2.2. New Inventions In Drug Therapy
      • 4.6.7.2.3. Possible Risk
    • 4.6.7.3. Opportunities
      • 4.6.7.3.1. Side Effects Associated With Drug Therapy
      • 4.6.7.3.2. New Developments Eliminate The Need For Repeat Procedures
• 4.7. Steroid Eluting Electrodes
  • 4.7.1. Drivers
    • 4.7.1.1. Increasing Demand For Pacemakers And Icds
    • 4.7.1.2. Continuously Monitors The Heart
    • 4.7.1.3. Increased Longevity
  • 4.7.2. Restraints
    • 4.7.2.1. Advantages Of Non Steroid Eluting Electrodes
    • 4.7.2.2. Monopoly By A Few Companies
  • 4.7.3. Key Players And Their Recent Developments
  • 4.7.4. Implantable Cardioverter Defibrillator
    • 4.7.4.1. Drivers
      • 4.7.4.1.1. Prevention Of Inflammation
      • 4.7.4.1.2. Improved Diagnosis Of Cardiac Problem
    • 4.7.4.2. Restraints
      • 4.7.4.2.1. Limited Choice In Product Variety
      • 4.7.4.2.2. Restrained Promotion About Their Effectiveness
  • 4.7.5. Deep Brain Stimulator
    • 4.7.5.1. Drivers
      • 4.7.5.1.1. Treatment Provides Therapeutic Benefits
      • 4.7.5.1.2. Varied Applications
    • 4.7.5.2. Restraints
      • 4.7.5.2.1. Fear Of Side Effects
• 4.8. Closed Loop Glucose Monitor And Insulin Pump
  • 4.8.1. Drivers
    • 4.8.1.1. Minimal Invasiveness Leads To Convenience
    • 4.8.1.2. Hassle Free Diabetes Management
    • 4.8.1.3. Treatment Made Reliable
    • 4.8.1.4. A Killer Disease
    • 4.8.1.5. Monitoring Of Diabetes Combating Therapies
    • 4.8.1.6. Monitoring Of Extreme Levels Of Glucose
    • 4.8.1.7. Insurance Coverage
  • 4.8.2. Restraints
    • 4.8.2.1. Human Intervention Necessary
    • 4.8.2.2. The Combination Product Expensive
    • 4.8.2.3. New Technology
  • 4.8.3. Opportunities
    • 4.8.3.1. Under Penetration Of The Product In The U.S.
    • 4.8.3.2. Further Development Of Technology
  • 4.8.4. Key Players And Their Recent Developments

5. Drug-Device Combination Application

• 5.1. Cardiovascular Treatment
  • 5.1.1. Drivers
    • 5.1.1.1. Provide Better Treatment
    • 5.1.1.2. Increasing Number Of Cardiovascular Treatments
    • 5.1.1.3. Increased Comfort To The Elderly
    • 5.1.1.4. Diabetes Patients With Cardiovascular Problems
  • 5.1.2. Restraints
    • 5.1.2.1. Restriction Enforced By Fda
    • 5.1.2.2. Post Surgery Medication Adds Up To The Cost
    • 5.1.2.3. Prevention Of Cardiovascular Diseases
  • 5.1.3. Coronary Angioplasty
    • 5.1.3.1. Drivers
      • 5.1.3.1.1. Reduced Risk Of Sudden Heart Attacks
      • 5.1.3.1.2. Treatment Independent Of Economic Situation
    • 5.1.3.2. Restraints
      • 5.1.3.2.1. Not Recommended For Angina
      • 5.1.3.2.2. Expensive Nature Of Treatment
  • 5.1.4. Tachycardia Management
    • 5.1.4.1. Drivers
      • 5.1.4.1.1. Reduced Chances Of Heart Failure
      • 5.1.4.1.2. Diagnosis Has Opened Up New Avenues
    • 5.1.4.2. Restraints
      • 5.1.4.2.1. Unknown Potential Market Size
      • 5.1.4.2.2. Lack Of Awareness
  • 5.1.5. Pediatric Bradycardia
    • 5.1.5.1. Drivers
    • 5.1.5.2. Restraints
• 5.2. Non Cardiovascular Treatments
  • 5.2.1. Drivers
    • 5.2.1.1. Several New Treatments For Non Cardiovascular Diseases
    • 5.2.1.2. Issue Of Reimbursement
    • 5.2.1.3. Untapped Markets
    • 5.2.1.4. Reap Full Potential Of Present Technologies
  • 5.2.2. Restraints
    • 5.2.2.1. Partnership Issues
    • 5.2.2.2. Rising Popularity Of Alternative Therapies
    • 5.2.2.3. Underlying Cause Of Disease Not Known
  • 5.2.3. Peripheral Arterial Disease (Pad)
    • 5.2.3.1. Symptoms Of The Disease Are Often Confused With General Problems Of Old Age.
  • 5.2.4. Intravascular Access
    • 5.2.4.1. Drivers
      • 5.2.4.1.1. Indispensable In Modern Day Medical Imstitutions
      • 5.2.4.1.2. Prevents Infection Along With Serving Other Purposes
      • 5.2.4.1.3. Agents Used To Coat The Catheters Have Already Been Tested
      • 5.2.4.1.4. New Developments Give Increased Mobility
    • 5.2.4.2. Restraints
      • 5.2.4.2.1. Following Guidelines For Use Of Uncoated Catheters Eliminates Need For Coated Ones
      • 5.2.4.2.2. Increasing Minimally Invasive Surgeries
  • 5.2.5. Neurodegenerative Diseases
    • 5.2.5.1. Drivers
      • 5.2.5.1.1. New Opportunities
      • 5.2.5.1.2. Large Segment Of Population Afflicted With The Disease
• 5.3. Urological Treatments
  • 5.3.1. Drivers
    • 5.3.1.1. Wide Array Of Applications
    • 5.3.1.2. Various Factors Boost The Market
    • 5.3.1.3. Improved Efficiency Of New Treatments
  • 5.3.2. Restraints
    • 5.3.2.1. Urological Diseases Overshadowed By Cardiovascular Diseases
  • 5.3.3. Dialysis
    • 5.3.3.1. Drivers
      • 5.3.3.1.1. High Per Capita Revenue
      • 5.3.3.1.2. Reimbursement Plans Activated
      • 5.3.3.1.3. Convenience Associated With Home Dialysis
    • 5.3.3.2. Restraints
  • 5.3.4. Urinary Tract Infections
    • 5.3.4.1. Drivers
      • 5.3.4.1.1. Women Prone To Such Infections
      • 5.3.4.1.2. Prevention Better Than Cure
    • 5.3.4.2. Restraints
      • 5.3.4.2.1. Diagnosing Urinary Tract Infections Is Still An Issue
• 5.4. Bone Treatment
  • 5.4.1. Drivers
    • 5.4.1.1. High Success Ratio To Drive The Market
    • 5.4.1.2. Degenerative Diseases To Push The Market Forward
    • 5.4.1.3. Several Factors Are Promoting Their Usage
    • 5.4.1.4. Transmission Of Fatal Diseases Can Be Avoided
  • 5.4.2. Restraints
    • 5.4.2.1. Therapies Are Not Of The Same Standard As Allograft And Autografts
  • 5.4.3. Joint Arthroplasty
    • 5.4.3.1. Drivers
      • 5.4.3.1.1. Deep Prosthetics Infections Reduced To 1.6% From 6%
      • 5.4.3.1.2. Obesity Increasing The Demand For Joint Arthroplasty
      • 5.4.3.1.3. Improved Accuracy Gives Confidence To Its Application
    • 5.4.3.2. Restraints
      • 5.4.3.2.1. Rising Necessity Of Revision Surgeries
  • 5.4.4. Spine Fusion
• 5.5. Antimicrobial Applications
  • 5.5.1. Drivers
    • 5.5.1.1. Application Is Increasing Over Time
    • 5.5.1.2. Rising Number Of Diabetic Patients
    • 5.5.1.3. Infection Prevention Leads To Faster Recovery
    • 5.5.1.4. Reduced Expenditure Incurred By Hospitals
  • 5.5.2. Restraints
    • 5.5.2.1. Lack Of Resources In Urban Safety-Net Hospitals
    • 5.5.2.2. Developing Countries Have Not Adopted These Treatments
  • 5.5.3. Wound Care
    • 5.5.3.1. Drivers
      • 5.5.3.1.1. Several Factors Giving Boost To The Market
      • 5.5.3.1.2. Slowing Down In Demand Is Not Possible
    • 5.5.3.2. Restraints
  • 5.5.4. Skin Substitutes
    • 5.5.4.1. Drivers
      • 5.5.4.1.1. Infection Risk Is Eliminated
      • 5.5.4.1.2. Faster Healing Reduces Period Of Convalescence
    • 5.5.4.2. Restraints
    • 5.5.4.2.1. Reimbursement Issue Is A Restraining Factor
• 5.6. Cancer Treatment
  • 5.6.1. Drivers
    • 5.6.1.1. Increase In The Number Of Cancer Patients
    • 5.6.1.2. Treatment Using Pdt Is Non Invasive And Patient Friendly
    • 5.6.1.3. Risks Associated With The Treatment Is Minimal
    • 5.6.1.4. Treatment Without Risk Of Side Effects
  • 5.6.2. Restraints
    • 5.6.2.1. Limited Applications
    • 5.6.2.2. Possibility Of Inadequate Number Of Health Care Professionals
    • 5.6.2.3. New Pharmaceutical Inventions
  • 5.6.3. Barrett' s Esophagus
    • 5.6.3.1. Drivers
      • 5.6.3.1.1. Increasing Prevalence Of The Disease
      • 5.6.3.1.2. Several Advantages Of The Treatment
    • 5.6.3.2. Restraints
      • 5.6.3.2.1. Improved Efficiency Of The Treatment
  • 5.6.4. Skin Cancer
    • 5.6.4.1. Drivers
      • 5.6.4.1.1. Increased Diagnosis Of Skin Cancer Cases Will Give A Boost To The Market
      • 5.6.4.1.2. Broadening Variety Of Cancer Patients
      • 5.6.4.1.3. Prevalence Of Such Cancer In Developed Countries
      • 5.6.4.1.4. Application Not Limited To One Disease
    • 5.6.4.2. Restraints
      • 5.6.4.2.1. Phototoxicity
      • 5.6.4.2.2. Limited Market Potential
  • 5.6.5. Head And Neck Cancer
    • 5.6.5.1. Drivers
      • 5.6.5.1.1. Preferred Treatment In Certain Cases
      • 5.6.5.1.2. Less Risk Of Long Term Infections
    • 5.6.5.2. Restraints
      • 5.6.5.2.1. Patients Revert To Conventional Treatments If Cancer Relapses
      • 5.6.5.2.2. Low Success Rate Due To Co Morbidity
• 5.7. Skin Care/Treatment
  • 5.7.1. Drivers
    • 5.7.1.1. Increasing Demand For Skin Care Therapy
    • 5.7.1.2. Treatment Is Done At The Inner Dermis Layer
  • 5.7.2. Restraints
    • 5.7.2.1. Loyal Customers Of Cosmetic Companies
    • 5.7.2.2. Limited Marketing Activities For Pdt
  • 5.7.3. Opportunities
    • 5.7.3.1. Improved Marketing Activities
    • 5.7.3.2. Untapped Potential In Developing Countries
  • 5.7.4. Actinic Keratoses
    • 5.7.4.1. Drivers
      • 5.7.4.1.1. High Demand In The U.S. And Australia
      • 5.7.4.1.2. Enhanced Treatment
      • 5.7.4.1.3. Elimination Of Risk Of Skin Cancer
      • 5.7.4.1.4. Added Advantage Of Cosmetic Enhancement
    • 5.7.4.2. Restraints
      • 5.7.4.2.1. Demand Is Not Global
      • 5.7.4.2.2. Repeated Procedures Make The Patients Photosensitive
  • 5.7.5. Photorejuvenation
• 5.8. Ophthalmic Treatment
  • 5.8.1. Drivers
    • 5.8.1.1. Increased Demand From The Ageing Population
    • 5.8.1.2. Offers Physical And Economical Advantages
  • 5.8.2. Restraints
    • 5.8.2.1. Repeated Treatments Required
  • 5.8.3. Pathologic Myopia
    • 5.8.3.1. Drivers
      • 5.8.3.1.1. One Of The Leading Causes Of Blindness In People Of Certain Races
      • 5.8.3.1.2. Photodynamic Therapy Is An Alternative Option
      • 5.8.3.1.3. Increased Preference By Sportspersons
    • 5.8.3.2. Restraints
      • 5.8.3.2.1. Repetetionof Procedures Will Add To The Cost
      • 5.8.3.2.2. Preference Of Contact Lenses Over Pdt
  • 5.8.4. Age Related Macular Degeneration
    • 5.8.4.1. Drivers
      • 5.8.4.1.1. Age Related Macular Degeneration Has The Potential Of Becoming A National Health Issue
      • 5.8.4.1.2. Non Invasive Nature Leads To No Pain And Inconvenience
      • 5.8.4.1.3. No Damage To The Retina
    • 5.8.4.2. Restraints
      • 5.8.4.2.1. Success Restricted By Certain Factors
      • 5.8.4.2.2. Non Recovery Of Normal 6/6 Vision
  • 5.8.5. Presumed Ocular Histoplasmosis
• 5.9. Diabetes Treatment
  • 5.9.1. Drivers
    • 5.9.1.1. Increasing Number Of Diabetes Patients
    • 5.9.1.2. Potential In Middle Income Countries
    • 5.9.1.3. New Generation Treatments Effective In Diabetic Patients
  • 5.9.2. Restraints
    • 5.9.2.1. Possible Restraining Factors In Future
    • 5.9.2.2. Limited Opportunity In Africa
  • 5.9.3. Opportunities
    • 5.9.3.1. Obesity And Increasing Age Of People
    • 5.9.3.2. Development In Technologies Will Reduce The Cost

6. Drug-Device Combination Market By Technology

• 6.1. Synthetic Bone Graft Substitutes
  • 6.1.1. Drivers
    • 6.1.1.1. Availability Of Several Types Enables Customized Usage
    • 6.1.1.2. Surgeons Have Several Options
    • 6.1.1.3. Applicable In Load Bearing Body Parts
    • 6.1.1.4. Foreign Substance Eliminated From The Body
    • 6.1.1.5. Increased Applications
  • 6.1.2. Restraints
    • 6.1.2.1. Do Not Possess Ideal Properties
    • 6.1.2.2. Possible Stunted Growth In Future
• 6.2. Demineralized Bone Matrix
  • 6.2.1. Driver
    • 6.2.1.1. Easy To Understand Technology
    • 6.2.1.2. Applicable For Different Types Of Bone Defects
    • 6.2.1.3. Growing Number Of Aged People
  • 6.2.2. Restraints
    • 6.2.2.1. Lack Of Osteoinductive Properties
    • 6.2.2.2. Competition From Other Procedures
• 6.3. Bone Morphogenic Proteins

7. Geography Analysis

• 7.1. The U.S. Drug-Device Combination Market
• 7.2. The European Drug-Device Combination Market
• 7.3. The Asian Drug Device Combination Market

8. Company Profiles

• 8.1. Integra Lifesciences Holdings Corp
• 8.2. Smith & Nephew Plc
• 8.3. Angiotech Pharmaceuticals, Inc
• 8.4. 3m
• 8.5. Abbott Laboratories
• 8.6. Acrymed
• 8.7. Allosource
• 8.8. Lifecell Corp
• 8.9. Nucryst Pharmaceuticals, Inc
• 8.10. Orbusneich Co., Ltd
• 8.11. Organogenesis, Inc
• 8.12. Osteotech, Inc
• 8.13. Forticell Bioscience, Inc
• 8.14. Spire Biomedical Inc
• 8.15. St. Jude Medical Inc
• 8.16. Agion Technologies, Inc
• 8.17. Apatech
• 8.18. Biomet Orthopedics, Inc
• 8.19. Biosensors
• 8.20. Biotronik
• 8.21. C.R. Bard, Inc
• 8.22. Kiadis Pharma B.V
• 8.23. Corin
• 8.24. Covalon
• 8.25. Covidien Ltd
• 8.26. Dusa Pharmaceuticals, Inc.
• 8.27. Depuy Orthopaedics Inc
• 8.28. Edwards Lifesciences Corp
• 8.29. Etex
• 8.30. Ethicon, Inc.
• 8.31. Exactech Inc.
• 8.32. Stryker Corporation
• 8.33. Davol Inc.
• 8.34. Sungwon Medical Co., Ltd
• 8.35. Tei Biosciences, Inc.
• 8.36. Vygon S.A
• 8.37. W.L. Gore & Associates Inc.
• 8.38. Wright Medical Group, Inc.
• 8.39. Xtent
• 8.40. Collagen Matrix, Inc.
• 8.41. Cook Critical Care, Inc.
• 8.42. Arrow International
• 8.43. Biometrix Medical
• 8.44. Zimmer Holding, Inc.
• 8.45. Medtronic, Inc.
• 8.46. Qlt Inc.
• 8.47. Cook Medical
• 8.48. Boston Scientific Corporation
• 8.49. Atrium Medical Corporation
• 8.50. Cordis Corporation
• 8.51. Synthes, Inc.

9. Patent Analysis

• 9.1. U.S. Patents
• 9.2. E.U. Patents
• 9.3. Asia Patents

Appendix

List Of Figures:

• Figure 1 Parental Structure Of Drug-Combination Market
• Figure 2 Evolution Of Drug-Device Combination
• Figure 3 Factors Affecting The Drug-Device Combination Market
• Figure 4 Current Favorability For Drug-Device Combination Market
• Figure 5 Market Potential For Drug-Device Combination Market
• Figure 6 Trends In R&D For Drug-Device Combination Market
• Figure 7 Global Market Share Of Key Players
• Figure 8 Global Segmentation Of Drug-Device Combination Patents

List Of Tables:

• Summary Table Global Drug Device Combination Market 2007 - 2014 ($Millions)
• Table 1 Global Antimicrobial Catheter Market, By Products 2007 - 2014 ($ Millions)
• Table 2 Global Antimicrobial Catheter Market, By Geography 2007 - 2014 ($Millions)
• Table 3 Major Players And Product Developments
• Table 4 Global Urological Catheter Market, By Products 2007 - 2014 ($ Millions)
• Table 5 Global Urological Catheter Market, By Geography 2007 - 2014 ($ Millions)
• Table 6 Major Players And Product Developments
• Table 7 Global Dialysis Catheter Market, By Products 2007 - 2014 ($ Millions)
• Table 8 Global Dialysis Catheter Market, By Geography 2007 - 2014 ($ Millions)
• Table 9 Major Players And Product Developments
• Table 10 Global Hemodialysis Catheter Market, By Geography 2007 - 2014 ($ Millions)
• Table 11 Global Peritoneal Catheter Market, By Geography, 2007 - 2014 ($ Millions)
• Table 12 Global Urinary Catheter Market, By Products 2007 - 2014 ($ Millions)
• Table 13 Global Urinary Catheter Market, By Geography 2007 - 2014 ($ Millions)
• Table 14 Major Players And Product Developments
• Table 15 Global Indwelling Catheter Market, By Geogrphy 2007 - 2014 ($ Millions)
• Table 16 Major Players And Product Developments
• Table 17 Global External Catheter Market, By Gography 2007 - 2014 ($ Millions)
• Table 18 Global Oximetry Catheter Market, By Products 2007 - 2014 ($ Millions)
• Table 19 Global Thermodilution Catheter Market By Geography 2007 - 2014 ($ Millions)
• Table 20 Major Players And Product Developments
• Table 21 Global Advanced Wound Care Products Market, By Products 2007 - 2014 ($ Millions)
• Table 22 Global Advanced Wound Care Products Market, By Geography 2007 - 2014 ($ Millions)
• Table 23 Major Players And Product Developments
• Table 24 Global Antibiotic Wound Care Market, By Geography 2007 - 2014 ($ Millions)
• Table 25 Major Players And Product Developments
• Table 26 Global Bone Graft Substitues Market, By Products 2007 - 2014 ($ Millions)
• Table 27 Global Bone Graft Substitues Market, By Geography 2007 - 2014 ($ Millions)
• Table 28 Major Players And Product Developments
• Table 29 Global Ceramic Based Bone Graft Substitutes Market, By Products 2007 - 2014 ($ Millions) .
• Table 30 Global Ceramic Based Bone Graft Substitutes Market, By Geography 2007 - 2014 ($ Millions)
• Table 31 Global Ceramic Based Bone Graft Substitutes Mixed With Calcium Phosphate Market, By Geography 2007 - 2014 ($ Millions)
• Table 32 Major Players And Product Developments
• Table 33 Global Allograft Based Bone Graft Substitutes Market, By Geography 2007 - 2014 ($ Millions)
• Table 34 Major Players And Product Developments
• Table 35 Global Factors Based Bone Graft Substitutes, By Geography 2007 - 2014 ($ Millions)
• Table 36 Major Players And Product Developments
• Table 37 Global Cell Based Bone Graft Substitutes Market, By Geography 2007 - 2014 ($ Millions)
• Table 38 Major Players And Product Developments
• Table 39 Global Antibiotic Bone Cements Market, By Geography 2007 - 2014 ($ Millions)
• Table 40 Major Players And Product Developments
• Table 41 Global Drug Eluting Stents Market, By Products 2007 - 2014 ($ Millions)
• Table 42 Global Drug Eluting Stents Market, By Geography 2007 - 2014 ($ Millions)
• Table 43 Global Coronary Stents Market, By Geography 2007 - 2014 ($ Millions)
• Table 44 Major Players And Product Developments
• Table 45 Global Peripheral Vascular Stent Market By Geography 2007 - 2014 ($ Millions)
• Table 46 Global Photodynamic Therapy Market, By Products 2007 - 2014 ($ Millions)
• Table 47 Global Photodynamic Therapy Market, By Geography 2007 - 2014 ($ Millions)
• Table 48 Major Players And Product Developments
• Table 49 Global Aminolevulinic Acid Market, By Geography 2007 - 2014 ($ Millions)
• Table 50 Global Porfimer Sodium Market, By Geography 2007 - 2014 ($ Millions) .
• Table 51 Major Players And Product Developments
• Table 52 Global Verteporfin Market, By Geography 2007 - 2014 ($ Millions)
• Table 53 Global Steroid Eluting Electrodes Market By Products 2007 - 2014 ($ Millions)
• Table 54 Global Steroid Eluting Electrodes Market By Geography 2007 - 2014 ($ Millions)
• Table 55 Major Players And Product Developments
• Table 56 Global Implantable Cardioverter Market, By Geography 2007 - 2014 ($ Millions)
• Table 57 Global Deep Brain Stimulator Market, By Geography 2007 - 2014 ($ Millions)
• Table 58 Global Closed Loop Glucose Monitor And Insulin Pump Market, By Geography 2007 - 2014 ($ Millions)
• Table 59 Major Players And Product Developments
• Table 60 Global Cardiovasular Treatment Market, By Application 2007 - 2014 ($ Millions)
• Table 61 Global Non Cardiovascular Treatment Market, By Application 2007 - 2014 ($ Millions)
• Table 62 Global Urologicaltreatment Market, By Application 2007 - 2014 ($ Millions)
• Table 63 Global Bone Treatment Market, By Application 2007 - 2014 ($ Millions)
• Table 65 Global Cancer Treatment Market, By Application 2007 - 2014 ($ Millions) Table 66 Global Skin Care/Treatment Market, By Application 2007 - 2014 ($ Millions)
• Table 67 Global Ophthalmic Tretment Market, By Application 2007 - 2014 ($ Millions) Table 68 Global Bone Graft Substitutes Market, By Technology 2007 - 2014 ($ Millions) Table 69 Global Drug-Device Combination Market 2007 - 2014 ($ Millions)
• Table 70 U.S. Drug-Device Combination Market 2007 - 2014 ($ Millions)
• Table 71 European Drug-Device Combination Market 2007 - 2014 ($ Millions)
• Table 72 Asian Drug-Device Combination Market 2007 - 2014 ($ Millions)
• Table 73 Integra Lifesciences Product Portfolio
• Table 74 Integra Lifesciences Strategies
• Table 75 Smith & Nephew' s Product Portfolio
• Table 76 Smith & Nephew Strategies
• Table 77 Angiotech Pharmaceuticals' Product Portfolio
• Table 78 Angiotech Pharmaceuticals Strategies
• Table 79 3m' s Product Portfolio
• Table 80 3m Strategies
• Table 81 Abbott Laboratories' Product Portfolio
• Table 82 Abbott Laboratories Strategies
• Table 83 Acrymed' s Product Portfolio
• Table 84 Allosource' s Product Portfolio
• Table 85 Allosource Strategies
• Table 86 Lifecell Corp.' S Product Portfolio
• Table 87 Nucryst Pharmaceuticals Product Portfolio
• Table 88 Orbusneich Co., Ltd. Product Portfolio
• Table 89 Organogenesis, Inc' s Product Portfolio
• Table 90 Osteotech, Inc.' S Product Portfolio
• Table 91 Spire Biomedical' s Product Portfolio
• Table 92 St. Jude' s Product Portfolio
• Table 93 St. Jude Strategies
• Table 94 Agion Technologies Product Portfolio
• Table 95 Agion Technologies, Inc. Strategies
• Table 96 Apatech' s Product Portfolio
• Table 97 Biomet Orthopedics' Product Portfolio
• Table 98 Biosensors' Product Portfolio
• Table 99 Biosensors Strategies
• Table 100 Biotronik' s Product Portfolio
• Table 101 Biotronik Strategies
• Table 102 C.R. Bard' s Product Portfolio
• Table 103 Biotronik Strategies
• Table 104 Kiadis Pharma' s Product Portfolio
• Table 105 Corin Product Portfolio
• Table 106 Corin Strategies
• Table 107 Covalon' s Product Portfolio
• Table 108 Covalon Strategies
• Table 109 Covidien' s Product Portfolio
• Table 110 Covidien Strategies
• Table 111 Dusa Pharmaceuticals' Product Portfolio
• Table 112 Dusa Pharmaceuticals Strategies
• Table 113 Depuy Orthopaedics' Product Portfolio
• Table 114 Edwards Lifesciences Product Portfolio
• Table 115 Etex' s Product Portfolio
• Table 116 Etex Strategies
• Table 117 Ethicon' s Product Portfolio
• Table 118 Exactech' s Product Portfolio
• Table 119 Stryker' s Product Portfolio
• Table 120 Davol' s Product Portfolio
• Table 121 Sungwon' s Medical Product Portfolio
• Table 122 Tei Biosciences Product Portfolio
• Table 123 Vygon' s Product Portfolio
• Table 124 W.L. Gore & Associates Product Portfolio
• Table 125 W.L. Gore & Associates Strategies
• Table 126 Wright Medical' s Product Portfolio
• Table 127 Xtent' s Product Portfolio
• Table 128 Collagen' s Matrix Product Portfolio
• Table 129 Cook Critical Care' s Product Portfolio
• Table 130 Arrow International' s Product Portfolio
• Table 131 Biometrix' s Product Portfolio
• Table 132 Zimmer' s Product Portfolio
• Table 133 Zimmer Strategies
• Table 134 Medtronic' s Product Portfolio
• Table 135 Medtronic Strategies
• Table 136 Qlt' s Product Portfolio
• Table 137 Cook Medical' s Product Portfolio
• Table 138 Cook Medical Strategies
• Table 139 Boston Scientific' s Product Portfolio
• Table 140 Boston Scientific Strategies
• Table 141 Atrium Medical' s Product Portfolio
• Table 142 Atrium Medical Strategies
• Table 143 Cordis Corporation' s Product Portfolio
• Table 144 Synthes Product Portfolio